A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program could run into problems with voluntary participation and concerns about expense.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity medications.

Trump administration eyes Medicare and Medicaid coverage for weight loss drugs like Wegovy and Ozempic in a five-year pilot starting 2026.